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Aggregation of amyloid beta and loss of cholinergic innervation in the brain are predominant components of Alzheimer’s disease
pathology and likely underlie cognitive impairment. Acetylcholinesterase inhibitors are one of the few treatment options
for Alzheimer’s disease, where levels of available acetylcholine are enhanced to counteract the cholinergic loss. However, these
inhibitors show limited clinical efficacy. One potential explanation for this is a concomitant dysregulation of cholinergic receptors
themselves as a consequence of the amyloid beta pathology. We tested this hypothesis by examining levels of M1 muscarinic acetyl-
choline receptors in the temporal cortex from seven Alzheimer’s disease and seven non-disease age-matched control brain tissue
samples (control: 856 2.63 years old, moderate Alzheimer’s disease: 8462.32 years old, P-value ¼ 0.721; eight female and six
male patients). The samples were categorized into two groups: ‘control’ (Consortium to Establish a Registry for Alzheimer’s
Disease diagnosis of ‘No Alzheimer’s disease’, and Braak staging pathology of I–II) and ‘moderate Alzheimer’s disease’
(Consortium to Establish a Registry for Alzheimer’s Disease diagnosis of ‘possible/probable Alzheimer’s disease’, and Braak staging
pathology of IV). We find that in comparison to age-matched controls, there is a loss of M1 muscarinic acetylcholine receptors in
moderate Alzheimer’s disease tissue (control: 2.176 0.27 arbitrary units, n¼ 7, Mod-AD: 0.836 0.16 arbitrary units, n¼ 7, two-
tailed t-test, t¼ 4.248, P¼ 0.00113). Using a functional rat cortical brain slice model, we find that postsynaptic muscarinic acetyl-
choline receptor function is dysregulated by aberrant amyloid beta-mediated activation of metabotropic glutamate receptor 5.
Crucially, blocking metabotropic glutamate receptor 5 restores muscarinic acetylcholine receptor function and object recognition
memory in 5XFAD transgenic mice. This indicates that the amyloid beta-mediated activation of metabotropic glutamate receptor 5
negatively regulates muscarinic acetylcholine receptor and illustrates the importance of muscarinic acetylcholine receptors as a po-
tential disease-modifying target in the moderate pathological stages of Alzheimer’s disease.
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LSN¼LSN2300979; mAChRs¼muscarinic acetylcholine receptors; mGluR5 ¼ metabotropic glutamate receptor 5; MPEP ¼ 2-
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Introduction
Alzheimer’s disease causes neurodegeneration in the brain
and represents the major, and as yet incurable, form of
dementia. A striking feature of the disease is the loss of
cholinergic innervation of the cortex, which occurs along-
side the pathological progression of Alzheimer’s disease.
The ‘cholinergic hypothesis of Alzheimer’s disease’ has ac-
cordingly directed the development of clinically approved
acetylcholinesterase inhibitors that function to enhance
available acetylcholine in synapses. However, acetyl-
cholinesterase inhibitors are fundamentally limited in their
clinical efficacy (Bond et al., 2012), indicating that the
loss of acetylcholine alone does not account for the cho-
linergic dysfunction. Thus, whilst acetylcholine abundance
is doubtlessly important, functional impairment of the
acetylcholine receptor itself in the synapse may also play
a role in Alzheimer’s disease. Therefore, it is of interest
to determine whether muscarinic acetylcholine receptor
(mAChR) dysfunction features in Alzheimer’s disease, and
if so whether this receptor can be targeted as a disease-
modifying strategy.
The M1 mAChR is a sub-family of G-protein-coupled
mAChRs. They operate through a Gi/Gq signalling
cascade, mobilizing Ca2þ from internal Ca2þ stores
(Caulfield, 1993). The activation of mAChRs induces
long-term synaptic plasticity in the perirhinal cortex, an
area pivotal for novel object recognition memory
(Warburton et al., 2003). Indeed, blocking mAChRs
causes deficits in object recognition memory (Warburton
et al., 2003). Given that this particular form of memory
is highly sensitive to disruption in the early stages of
Alzheimer’s disease (Dickerson et al., 2017), and the peri-
rhinal cortex is subject to volume loss in Alzheimer’s dis-
ease (Juottonen et al., 1998), this provides an intriguing
putative link between impaired mAChR function and
memory deficits in Alzheimer’s disease.
At the molecular level, activation of mAChRs negative-
ly regulates synaptic N-methyl-D-aspartate receptor
(NMDAR) function (Jo et al., 2010) and glycogen syn-
thase kinase 3 signalling (De Sarno et al., 2006), a key
component in a mechanism that drives tauopathy in the
brain (Hernandez et al., 2012). Critically, M1 mAChR
function is inhibited by aberrant activation of metabo-
tropic glutamate receptor 5 (mGluR5) in the perirhinal
cortex (Jo et al., 2006). This is important as mGluR5 has
been shown to act as a co-receptor for amyloid beta (Ab)
at the postsynaptic terminal (Um et al., 2013; Haas and
Graphical Abstract
2 | BRAIN COMMUNICATIONS 2020: Page 2 of 13 J. H. Yi et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article/2/2/fcaa058/5836506 by U
niversity of Bristol Library user on 18 August 2020
Strittmatter, 2016), playing an intermediary role between
Ab and intracellular signalling cascades that lead to syn-
apse loss and neurodegeneration (Um et al., 2013; Haas
and Strittmatter, 2016). Therefore, mGluR5 may be
involved in the pathological impairment of mAChR in
the perirhinal cortex in Alzheimer’s disease.
To test this hypothesis, we first investigated whether
M1 mAChR, the dominant form of mAChR in the brain,
is aberrantly regulated in the moderate pathological
stages of Alzheimer’s disease. We find a reduction in M1
mAChR protein expression in post-mortem temporal cor-
tical tissue from patients with moderate-stage Alzheimer’s
disease. We also find that Ab oligomers facilitate the ab-
errant activation of mGluR5, consequently leading to
weakening of postsynaptic M1 mAChR function in the
perirhinal cortex. Furthermore, systemic infusion of an
mGluR5-negative allosteric modulator [LSN2300979
(LSN)] rescues the otherwise impaired object recognition
memory in the 5XFAD (familial Alzheimer’s disease)
transgenic (TG) mouse model of Alzheimer’s disease path-
ology. Thus, our results suggest that inhibition of
mGluR5 is beneficial for mAChR function and disease
modification in moderate stages of Alzheimer’s disease.
Materials and methods
Post-mortem brain tissue
Human post-mortem brain tissue was provided by the
South West Dementia Brain Bank (University of Bristol,
UK), with local Research Ethics Committee approval. A
total of 200mg of non-specified temporal cortex samples
from 14 patient brain tissue donations were used for this
study (8 female and 6 male patients). The samples were
categorized as ‘control’ or ‘moderate Alzheimer’s disease’.
All control samples had a CERAD diagnosis (Mirra
et al., 1991) of ‘No Alzheimer’s disease’, and Braak stag-
ing (Braak and Braak, 1995) pathology of I–II. All mod-
erate Alzheimer’s disease samples had a CERAD
diagnosis of ‘possible/probable Alzheimer’s disease’, and
Braak staging pathology of IV. No differences in age
(control: 856 2.63 years old, moderate Alzheimer’s dis-
ease: 8462.32 years old, P-value ¼ 0.721, ‘data not
shown’) or ‘post-mortem’ delay (control: 45.786 4.78 h
old, moderate Alzheimer’s disease: 44.28611.34 h, P-
value ¼ 0.209, ‘data not shown’) were detected between
control and moderate Alzheimer’s disease groups. Human
‘post-mortem’ frozen samples were lysed at room tem-
perature in sucrose/sodium dodecyl sulfate (SDS) buffer
(lysis buffer) containing 1% SDS, 0.1 g/ml sucrose, 1mM
Ethylenediaminetetraacetic acid (EDTA), protease inhibi-
tor cocktail at 1:10 (05892791001, Roche), phosphatase
inhibitor cocktail at 1:100 (P5726, Sigma) and the serine/
cysteine protease inhibitor phenylmethanesulfonyl fluoride
at 1:100 (PMSF, P7626; Sigma). Approximately 100mg
of tissue were lysed in 500ll of sucrose/SDS buffer.
Samples were then centrifuged at 16 g for 20min at
16C. Pellets were discarded, and supernatants were col-
lected in a fresh tube, constituting the stock solutions.
Stock solutions were diluted 1:10 in lysis buffer to gener-
ate the working concentration sample. Samples were ali-
quoted and stored at 80C until required. Protein levels
were quantified using bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific). Following electrophoresis using
sodium dodecyl sulphate-polyacrylamide gels, immunoblot
analysis were performed using the relevant antibodies and
visualized with chemiluminescence. The chemiluminescent
signal was detected using the G:Box Chemi XT4 imaging
system (Syngene, UK), and images were taken with
GeneSys software (Syngene, UK). The following primary
antibodies and dilutions were used: Anti-NR1 (1:1000,
Upstate, 06-31; Matsuno et al., 2015), Anti-GluA2
(1:1000, Millipore, MAB397; Park et al., 2007; Peng
et al., 2015), Anti-mGluR1 (1:1000, ProteinTech, 19955-
1-AP; Koochekpour et al., 2012), Anti-mGluR5 (1:2000,
Millipore, AB5675; Deschwanden et al., 2011), Anti-M1
mAChR (1:200, Millipore, AB5164; Takamori et al.,
2007; Molina et al., 2014) and Anti-postsynaptic density
95 (1:1000, Cell Signal, 3409; Martineau et al., 2018;
Subkhangulova et al., 2018). The following secondary
antibodies were used: Anti-mouse horseradish peroxidase
(HRP) conjugate (1:4000, Upstate, 12-349) and Anti-rab-
bit HRP conjugate (1:4000, Millipore, 12-348). Data pre-
sented in the figures are cropped; uncropped western blot
data are shown in Supplementary Fig. 1.
Animals
All procedures involving animals used for in vitro experi-
ments were performed in accordance with the UK
Animals (Scientific Procedures) Act, 1986. All experimen-
tal protocols were approved by the University of Bristol
Animal Welfare and Ethical Review Body. Animals were
housed in groups and exposed to the 12-h light/12-h
dark cycle. Animals were housed in controlled environ-
mental conditions with food and water available ad libi-
tum. Calcium imaging experiments were conducted using
organotypic slices prepared from P7–8 male Wistar rats.
Electrophysiology experiments were conducted using
acute slices prepared from P25–35 male Wistar rats.
Behavioural experiments were approved by the
Institutional Animal Care and Use Committee of Kyung
Hee University (Seoul, Republic of Korea). Mice were
housed four per cage and were allowed access to water
and food ad libitum. Animals were kept at a constant en-
vironment; temperature (236 1C) and relative humidity
(606 10%) under a 12-h light/dark cycle (lights on from
7:30A.M. to 7:30 P.M.). Behavioural experiments were
conducted using 6-month-old 5XFAD TG mice. These
animals overexpress mutant amyloid precursor protein
[K670N/M671L (Swedish), I716V (Florida) and V717I
(London mutation)], along with mutant PS1 with M146L
and L286V mutations. This results in the enhanced
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production of Ab with a rapid onset, with Ab typically
expressed intraneuronally at 1–2months of age (Oakley
et al., 2006).
Electrophysiology
Whole cell recording for holding current was performed
using acute perirhinal cortex slices (400 lm), which were
perfused with artificial CSF (continuously bubbled with
95% O2/5% CO2) containing 124mM NaCl, 3mM KCl,
26mM NaHCO3, 1.25mM NaH2PO4, 2mM CaCl2,
1mM MgSO4 and 10mM D-glucose. Recording electro-
des (5–6 MX) containing potassium gluconate filling solu-
tion were used to patch and voltage clamp rhinal sulcus,
layer II/III neurons. These were visualized using oblique
contrast microscopy, through an Olympus BX51-WU
microscope (Olympus, UK). The holding current record-
ing experiments were perfused with MK-801 (10 lM) and
tetrodotoxin (500 nM) in artificial CSF. The baseline of
holding current was recorded for 10min and then carba-
chol (CCh; 50 lM) applied for 5min in the perfusate.
Ab preparation
The Ab 1–42 peptide (Stratech, Ely, UK) was initially dis-
solved at a concentration of 1mg/ml in 100%
1,1,1,3,3,3-hexafluoro-2-propanol (Sigma-Aldrich). This
solution was then incubated for 1 h at room temperature,
with occasional vortexing at a moderate speed. The solu-
tion was then sonicated for 10min in a water bath soni-
cator. The 1,1,1,3,3,3-hexafluoro-2-propanol/peptide
solution was next dried under a gentle stream of nitrogen
gas. Then 100% dimethyl sulfoxide (DMSO) was then
used to resuspend the peptide, which was then incubated
at room temperature for 12min with occasional vortex-
ing. The final solution was aliquoted into smaller vol-
umes and stored at 80C. For a working solution, 500–
1000 ml (depending on the final concentration to be used)
Dulbecco’s phosphate-buffered saline (D-PBS; Invitrogen,
UK) was added to the peptide stock solution and incu-
bated for 2 h at room temperature to allow for peptide
aggregation. We have previously characterized this prep-
aration to contain 1–5 nM of low-n oligomers
(Whitcomb et al., 2015).
Organotypic brain slice culture
Perirhinal cortex organotypic slice cultures were prepared
from 7- to 8-day-old male Wistar rats. After decapitation,
the brain was immediately placed in ice-cold cutting solu-
tion (in mM: 238 sucrose, 2.5 KCl, 26 NaHCO3, 1
NaH2PO4, 5 MgCl2, 11 D-glucose and 1 CaCl2). A mid-
sagittal section of the brain was made, the rostral and
caudal parts were removed by single scalpel cuts 45 to
the dorsoventral axis and each half was glued by its cau-
dal end to a vibroslice stage (Campden Instruments,
Sileby, UK). Slices (350 lm) that included perirhinal,
entorhinal and temporal cortices were trimmed to create
sections centred on the rhinal sulcus, containing layers
I–V. Following washing, slices were plated on the top of
semipermeable membrane inserts (Millipore Corporation,
Bedford, MA, USA) within a six-well plate, which con-
tained culture medium, comprised 78.8% minimum essen-
tial medium, 20% heat-inactivated horse serum, 25mM
HEPES, 10mM D-glucose, 26mM NaHCO3, 2mM
CaCl2, 2mM MgSO4, 70 mM ascorbic acid, 1mg/ml insu-
lin, pH adjusted to 7.3 and 320–330 mOsm. The slices
were then cultured in an incubator (35C, 5% CO2) for
7–10 days in vitro. The medium was changed every
2 days. Neurons were transfected with GCaMP6 using a
biolistic gene gun (Helios Gene-gun system; Bio Rad,
USA) at days in vitro 3–4. Imaging assays were per-
formed 3–4 days after transfection.
Calcium imaging
Cultured perirhinal cortex slices were biolistically trans-
fected with GCaMP6, the genetically encoded calcium in-
dicator. Fluorescent images were captured using a BX51-
WU microscope fitted with an ORCA-ER digital camera
(Hamamatsu), at 1 frame/5 s. Following a 2min baseline,
10ml, 50 lM CCh was perfused onto the slice using a
gravity-fed dropper system. Fluorescence intensity was
quantified as a percentage of the normalized baseline,
using Image J (National Institutes of Health, Bethesda,
MD, USA).
Object recognition
The experimental apparatus consisted of a black rect-
angular open field (25 cm  25 cm  25 cm). The novel
object recognition task was carried out as described else-
where (Li et al., 2004; Barker and Warburton, 2011)
with slight modifications. For the novel object location
recognition test, mice were habituated to the open field
in the absence of objects but with an internal cue on one
of the four walls for 4 days. In the training phase, mice
were replaced in the same box but now with two distinct
objects. The objects consisted of a glass box and plastic
cylinder. Mice were allowed to freely explore the environ-
ment and the objects for 5min. After 3 h, mice were
placed back in the rectangular environment for the testing
phase. The two objects were again present, but one of
the two objects were now displaced to a novel spatial lo-
cation. Mice were allowed to freely explore the environ-
ment and the objects for 5min. Time spent exploring the
displaced and non-displaced objects were measured. Each
group’s ability to recognize the novel location was deter-
mined by dividing the mean time exploring the novel ob-
ject location by the mean of the total time exploring
both objects during the test session. This value was multi-
plied by 100 to obtain a percentage preference for the
novel object (Tnovel/Ttotal  100, Tfamiliar/Ttotal  100).
5XFAD TG mice were treated with oral administration
of LSN (30mg/kg) or vehicle (Veh) (0.9% saline) for
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8 days. On Days 4 and 5, animals from both groups
were habituated to test environment. Following training
on Day 6, animals were tested on Day 7, or in the 30-
day interval trial training took place on Day 37 and test-
ing took place on Day 38.
Statistical analysis
No statistical methods were used to predetermine sample
sizes. However, sample sizes were chosen based on previ-
ous studies published in the field by this laboratory and
others. No data points were excluded from the analysis.
Data pooled across slices are expressed as the mean 6
SEM. Statistics were based on two-tailed Student’s t tests
or one-way ANOVA followed by Tukey’s post hoc analy-
ses for multiple comparisons, unless otherwise indicated.
P < 0.05 was considered statistically significant.
Data availability
The data pertaining to the findings described here are
available from the corresponding author upon reasonable
request.
Results
Loss of M1 mAChR protein in
moderate Alzheimer’s disease
temporal cortex
Using temporal cortex brain tissue from moderate-stage
(Mod-Alzheimer’s disease) and non-disease patient brain
tissues (control), we determined total protein levels of key
excitatory synaptic receptors. We found a significant re-
duction in M1 mAChR in the Mod-Alzheimer’s disease
group [control: 2.176 0.27 arbitrary units (A.U.), Mod-
AD: 0.836 0.16A.U., two-tailed t-test, t¼ 4.248,
P¼ 0.00113, Fig. 1A], indicating a loss of this receptor
in moderate disease pathology. A similar effect was found
in the GluA2 subunit of a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (control:
1.096 0.07A.U., Mod-AD: 0.636 0.16A.U., two-tailed t-
test, t¼ 2.597, P¼ 0.0234, Fig. 1B). Interestingly, no such
loss was observed in GluN1 NMDARs (control:
0.976 0.12A.U., Mod-AD: 0.646 0.13A.U., two-tailed t-
test, t¼ 1.875, P¼ 0.853, Fig. 1C), which is consistent
with the widely accepted role NMDARs play in the
pathophysiology of Alzheimer’s disease (Wang and
Reddy, 2017). To determine whether the loss of mAChRs
represented a generalized loss of G-protein-coupled recep-
tors, we also assayed total levels of the related mGluR1
and mGluR5 subunits. Intriguingly, we found no differ-
ence in the levels of mGluR1 between the groups
(mGluR1; control: 0.846 0.11A.U., Mod-AD:
0.766 0.12A.U., two-tailed t-test, t¼ 0.311, P¼ 0.761,
Fig. 1D), but a significant reduction in mGluR5 (control:
2.26 0.44A.U., Mod-AD: 1.046 0.28A.U., two-tailed t-
test, t¼ 2.196, P¼ 0.0485, Fig. 1E). Furthermore, we
found no loss in levels of the postsynaptic density-95
protein, the prototypical postsynaptic protein and marker
of postsynaptic integrity (control: 1.36 0.09A.U., Mod-
AD: 1.036 0.18A.U., two-tailed t-test, t¼ 1.286,
P¼ 0.223, Fig. 1F). Together, these data indicate a select-
ive loss of mAChR, GluA2 and mGluR5 in the moderate
pathological progression of Alzheimer’s disease.
Ab impairs mAChR function
Organotypic cultured perirhinal cortex slices were biolisti-
cally transfected with the genetically encoded Ca2þ indi-
cator GCaMP6 (Chen et al., 2013), and we measured the
magnitude of fluorescence induced by Ca2þ mobilization
on ligand activation of mAChRs. Bath application of
CCh (50 lM), the mAChR agonist, induced a robust and
transient increase in Ca2þ both in the soma (open sym-
bols, peak fluorescence intensity as a % of baseline,
2056 16%, n¼ 13 cells from 10 slices) and dendrites
(closed symbols, peak fluorescence intensity as a % of
baseline 2666 23%, n¼ 8 dendrites from eight slices;
Fig. 2A). However, in slices treated for 2 h with 1–5 nM
Ab oligomers, the CCh-induced Ca2þ signal was signifi-
cantly reduced (open symbols, soma peak fluorescence in-
tensity as a % of baseline 1456 10%, n¼ 16 cells from
12 slices; closed symbols, dendrite peak fluorescence in-
tensity as a % of baseline 143612%, n¼ 8 dendrites
from 9 slices; Fig. 2B). The magnitude of CCh-induced
fluorescence was reduced in Ab-treated slices compared
with control slices, in both the soma (control versus Ab,
two-tailed t-test, t¼ 3.320, P¼ 0.00258) and dendrites
(control versus Ab, two-tailed t-test, t¼ 4.847,
P¼ 0.000213; Fig. 2C). This suggests that Ab oligomers
rapidly impair mAChR function.
Weakening of postsynaptic mAChR
function by Ab-induced
pathophysiology
To confirm this, we next analysed postsynaptic mAChR-
mediated holding current. Neurons were voltage clamped
at 70mV, and the injected current required to maintain
the holding current was monitored, before and after ap-
plication of CCh (50 lM). Perfusion of CCh caused a
rapid increase in negative holding current, indicative of
activation of mAChRs and consequent inward current
due to Ca2þ release from intracellular stores (peak de-
pression 626 14 pA, n¼ 5; Fig. 2D). In slices treated
for 2 h with 1–5 nM Ab oligomers, there was a signifi-
cant reduction in holding current change in response to
CCh (peak depression 246 3 pA, n¼ 5; Fig. 2E; control
versus Ab P¼ 0.0368), indicating that postsynaptic
mAChRs were no longer activated to the same extent as
that observed in the control condition. This suggests that
Ab dysregulates postsynaptic mAChR function, possibly
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Figure 1 Loss of M1 mAChR protein in human post-mortemmod-Alzheimer’s disease temporal cortex. (A) mAChR1 protein
levels are significantly reduced in the Mod-AD group (N¼ 7) compared to the control group (N¼ 7). (B) GluA2 protein levels are also
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through the impairment of classical G-protein-coupled re-
ceptor-mediated signal cascades or through the modula-
tion of the expression of the receptor itself. Since the
aberrant mobilization of Ca2þ by Ab is known to trigger
neurotoxicity in cell models (Demuro et al., 2005), we
wondered whether extracellular Ca2þ was important in
this effect. To test this, slices were exposed for 2 h with
1–5 nM Ab oligomers in Ca2þ-free artificial CSF and
CCh-induced holding current change was examined.
Interestingly, we found that under these conditions, Ab
had no impairing effects (63.86 14.3 pA, n¼ 10;
Fig. 2F). This suggests that Ab-mediated Ca2þ mobiliza-
tion causes mAChR dysfunction. The NMDAR is a cen-
tral postsynaptic Ca2þ regulator and a key conduit for
Ab-induced neuronal dysfunction (Wang and Reddy,
2017). Furthermore, the inhibition of NMDAR is benefi-
cial in Alzheimer’s disease and object recognition memory
in animal models of the disease (Romberg et al., 2012).
Therefore, we hypothesized that Ab-induced impairment
of mAChR function occurs in an NMDAR-dependent
manner. When slices were co-exposed to 1–5 nM Ab
oligomers and MK-801 (10 lM), the NMDAR channel
blocker, in normal Ca2þ-containing artificial CSF for 2 h,
we found that Ab did not impair the inward-holding cur-
rent change (77.2612.7 pA, n¼ 7; Fig. 2G). Together,
these data suggest that both extracellular Ca2þ and acti-
vation of NMDARs are essential for Ab-mediated
mAChR dysfunction.
Ab inhibits postsynaptic mAChR
function by aberrant activation of
mGluR5
The function and expression of mAChRs is regulated by
a number of different cellular processes, including phos-
phorylation and trafficking (van Koppen and Kaiser,
2003). A previous study also found that juvenile rat
mAChR function was down-regulated by aberrant activa-
tion of mGluR5, a group I metabotropic glutamate recep-
tor (Jo et al., 2006). Furthermore, evidence suggests that
mGluR5 and the synergistically regulated NMDAR func-
tion may be involved in Ab-mediated pathology and defi-
cits to object recognition memory in Alzheimer’s disease
(Alagarsamy et al., 2001; Renner et al., 2010; Hu et al.,
2014; Hamilton et al., 2016). We therefore hypothesized
that the weakening of mAChR function in Alzheimer’s
disease pathology is underpinned by the aberrant inter-
play between NMDAR and mGluR5 activation. We
applied the mGluR5 antagonist 2-methyl-6-(phenylethy-
nyl)pyridine (MPEP, 50 lM) to slices and then exposed
those slices for 2 h to 1–5 nM Ab oligomers. We found
that, in contrast to Ab treatment alone (Fig. 2B), inhib-
ition of mGluR5 restored CCh-induced Ca2þ signalling
(triangle symbols, soma peak fluorescence intensity as a
% of baseline 2546 37%, n¼ 7 cells from five slices/four
animals; dendrite peak fluorescence intensity as a % of
baseline 3106 49%, n¼ 5 dendrites from 5 cells;
Fig. 3A). The magnitudes of somatic and dendritic Ca2þ
on CCh application did not differ between the Ab with
MPEP group and untreated controls (soma: control ver-
sus Ab þ MPEP, two-tailed t-test, t ¼ 1.432,
P¼ 0.169; dendrite: control versus Ab þ MPEP, two-
tailed t-test, t ¼ 0.903, P¼ 0.386; Fig. 3B). Consistent
with these findings, we found that the application of
MPEP or the mGluR5-negative allosteric modulator LSN
(10 lM) prevented the Ab-mediated impairment of CCh-
induced inward-holding current change (peak depression
796 7pA, n¼ 6, control versus Ab þ MPEP P¼ 0.3;
Fig. 3C; peak depression 71.56 14.5 pA, n¼ 6; Ab þ
LSN; Fig. 3D). Together, these data indicate that the im-
pairment to mAChR function that is induced by Ab
occurs in unison with the aberrant activation of mGluR5,
and this is causally linked.
An mGluR5-negative allosteric
modulator restores novel object
recognition memory in 5XFAD TG
mouse
Since the inhibition of mGluR5 was critical to maintain
mAChR function, and the function of mAChRs is import-
ant in object recognition memory (Warburton et al., 2003),
we wondered what role mGluR5 might play in the widely
reported dysregulation of cognitive function by Ab
(McGowan et al., 2006). We therefore examined novel ob-
ject recognition memory in the 5XFAD TG mouse model.
Whilst there were no differences in exploration time be-
tween experimental groups [one-way ANOVA (Tukey’s
post hoc test) P¼ 0.1789, wild type (WT): 20.236 4.665 s,
n¼ 8; TG-Veh: 7.94662.279 s, n¼ 7; TG-LSN:
12.016 6.068 s, n¼ 7, Fig. 3E], there was a significant im-
pairment in object discrimination performance in the
Figure 1 Continued
significantly reduced in the Mod-AD group (N¼ 7) compared to the control group (N¼ 7). (C) GluN1 protein levels are not significantly
different between the Mod-AD group (N¼ 7) compared to the control group (N¼ 7). (D) mGluR1 protein levels are not significantly different
between the Mod-AD group (N¼ 7) and the control group (N¼ 7). (E) mGluR5 protein levels are significantly reduced in the Mod-AD group
(N¼ 7) compared with the control group (N¼ 7). (F) Postsynaptic density-95 protein levels are not significantly different between the Mod-AD
group (N¼ 7) and the control group (N¼ 7). Dots represent the value for each subject, and error bars represent the SEM. Significance level
(*P< 0.05) was determined using an unpaired two-tailed Student’s t-test. Insets show cropped representative immunoblots, full length blots
available in Supplementary Fig. 1. A.U. ¼ arbitrary units.
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Figure 2 Ab impairs mAChR function in the perirhinal cortex. (A) Quantification of GCaMP6-mediated Ca2þ fluorescence in
transfected neurons from perirhinal cortex organotypic culture. Following a 1-min baseline, CCh is perfused onto slices. Whilst this causes a
robust increase in fluorescence in control slices, (B) a much smaller magnitude of fluorescence increase is found in slices treated with Ab. (C)
Quantification in peak fluorescence change induces by CCh perfusion. Ab-Treated slices had statistically smaller peak fluorescence values in both
soma and dendrites compared with control slices. Bars represent6 SEM. (D) Change in holding current induced by CCh perfusion, normalized
to a 10-min baseline recording. Whilst CCh induces robust change in holding current, (E) CCh induces a modest change in holding current in
slices pre-exposed to Ab prior to recording (F). This impairment of holding current change by Ab is ameliorated in slices pre-exposed to Ab in
Ca2þ-free artificial CSF (G) and in slices pre-exposed to Ab in the presence of the NMDAR blocker MK-801. Figures represent pooled data
across separate experiments, with error bars representing6 SEM. Significance level (*P< 0.05) was determined by using an unpaired Student’s t-
test. Scale bar indicates 10 lm.
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Figure 3 Inhibition of mGluR5 prevents the Ab-mediated impairment of mAChR function and restores cognitive function.
(A) Quantification of GCaMP6-mediated Ca2þ fluorescence in transfected neurons from perirhinal cortex organotypic culture. Whilst there was
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5XFAD mice compared with WT mice [0.297160.07748
(n¼ 7) versus TG-Veh: 0.212260.1565 (n¼ 6),
P< 0.05, Fig. 3E]. Critically, this deficit was ameliorated in
5XFAD mice treated with LSN [TG-Veh versus TG-LSN:
0.388960.1234 (n¼ 6), P< 0.001, Fig. 3E]. Indeed, whilst
the WT animals showed an exploration preference for the
novel object (novel: 64.8606 3.874% versus familiar:
35.14063.874% object preference, Fig. 3F), the 5XFAD
mice displayed no such preference (novel:
39.39067.827% versus familiar: 60.6106 7.827% object
preference, Fig 3F). Importantly, the 5XFAD animals
treated with LSN displayed similar object preferences to
the WT control animals (novel: 69.4506 6.169% object
preference versus familiar: 30.5506 6.169% object prefer-
ence, Fig. 3F).
We wondered whether the restorative effects of
mGluR5 antagonism reflected a fundamental amelioration
of the disease state. To test this, we administered the
same drug regime but introduced a 30-day interval period
between the last drug infusion and training and testing.
Whilst there were no differences in exploration time be-
tween experimental groups [one-way ANOVA (Tukey’s
post hoc test) P¼ 0.275, WT: 18.6963.975 s, n¼ 8; TG-
Veh: 11.396 3.994 s, n¼ 7; TG-LSN: 11.706 2.472 s,
n¼ 7, Fig. 3G], there was a significant impairment in ob-
ject discrimination performance across the groups [one-
way ANOVA (Tukey’s post hoc test) P¼ 0.0102, WT:
0.271660.09399, n¼ 8; TG-Veh: 0.060256 0.05867,
n¼ 5; TG-LSN:-0.027186 0.03122, n¼ 6]. However,
there was no difference in discrimination performance be-
tween the 5XFAD Veh mice and those treated with LSN
(P¼ 6.134). Whilst the WT animals showed an explor-
ation preference for the novel object (novel:
63.58064.699% object preference versus familiar:
36.42064.699% object preference, Fig. 3H), the 5XFAD
mice displayed no such preference (novel:
46.99062.933% object preference versus familiar:
53.01062.933% object preference, Fig 3H). Importantly,
the 5XFAD animals treated with LSN also showed no
preference (novel: 48.6406 1.561% object preference ver-
sus familiar: 51.36061.561% object preference,
Fig. 3H). This indicates that whilst downregulation of
mGluR5 function is a putative means by which cognitive
function can be restored, the pathology is underpinned
by the constitutive aberrant activation of the receptor
and could therefore require sustained inhibition for re-
storative effect.
Discussion
Our protein assay data from moderate Alzheimer’s dis-
ease post-mortem brain tissue indicates a reduction in
M1 mAChR. This is consistent with a dysfunction of the
cholinergic transmission system occurring in the mild cog-
nitive impairment phase of the moderate pathological
stages of Alzheimer’s disease (Haense et al., 2012). On
the surface, our findings run counter to previous reports
describing no change (Mash et al., 1985) and an increase
(Overk et al., 2010) in M1 mAChRs in Alzheimer’s dis-
ease human tissue. Importantly, these studies assayed tis-
sue from patients with late-stage Alzheimer’s disease,
reinforcing our conclusion that mAChR dysregulation is
a feature of the progressive pathology of Alzheimer’s dis-
ease, and our present findings reflect moderate-stage
effects. Our postnatal and juvenile rat model studies are
indicative of the possible early events of Ab-mediated
dysfunction of mAChR. With this in mind, our results
raise the question as to whether the reduction in M1
mAChR is a consequence of pathophysiology and under-
lies cognitive impairment. mAChR-mediated synaptic
transmission plays a key role in the cellular mechanism
of object recognition in the rat perirhinal cortex
(Warburton et al., 2003). Interestingly, we previously
found that mGluR5 has a dominant role over M1
mAChR in this brain region in rats (Jo et al., 2006).
Since M1 mAChR and mGluR5 share the same Gi/Gq-
coupled signalling mechanisms, the aberrant activation of
mGluR5 function may dominantly sequester G proteins,
resulting in a lack of available G-protein coupling with
M1 mAChR. An alternative intriguing explanation is that
Ab disrupts M1 mAChR regulatory machinery, breaking
down the stabilization and recycling processes of mAChR
to the synapse (Gainetdinov et al., 2004). Thus, it is
Figure 3 Continued
only a modest increase in fluorescence in Ab-treated slices, there was a robust increase in fluorescence in Ab þ MPEP-treated slices. Scale bar
indicates 10 lm. (B) There was no statistically significant difference in peak fluorescence intensity induced by CCh perfusion between control
and Ab þ MPEP-treated slices. (C) Change in holding current induced by CCh perfusion. A robust change in holding current was induced by
CCh in slices treated with Ab þ MPEP (D) and in slices treated with Ab þ LSN. Holding current data illustrated in C and D were recorded from
acute perirhinal cortex slices from p25–35 Wistar rats. (E) Quantification of behavioural assessment of object recognition memory in 5XFAD
mice, comparing WT, vehicle (5XFAD þ vehicle) and LSN-treated (5XFAD þ LSN) animals. (F) Quantification of object preference between
novel and familiar objects, comparing the animal treatment groups. Whilst WTanimals showed a clear preference for the novel object, 5XFAD þ
vehicle animals did not. 5XFAD þ LSN animals showed a similar novel object preference to WTanimals. (G) Quantification of behavioural
assessment of object recognition memory across the experimental conditions outlined above, with a delay of 30 days introduced between vehicle
or LSN treatment and the training and testing. (H) Whilst WTanimals displayed a preference for novel objects, neither the vehicle-treated nor
LSN-treated animals did. Significance level (*P< 0.05; **P< 0.01; ***P< 0.001) was determined by using a one-way ANOVA with post hoc Tukey
analysis. Dots in E and G represent the value for each subject.
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plausible that Ab may cause weakening of M1 mAChR
function through mGluR5 activity and destabilization of
mAChR. However, it is not known whether and/or how
aberrant activation of mGluR5 function affects the ex-
pression of M1 mAChR in the progression of Alzheimer’s
disease.
Considering the slow progress in translating basic char-
acterization of Alzheimer’s disease pathophysiology to ef-
fective symptom and disease-modifying therapies, new
targets are required. Synapses serve as sites where key
pathological changes occur in Alzheimer’s disease (Selkoe,
2002). Defects in synaptic transmission and dendritic
spine structure are well-associated with the progression of
pathological events that greatly contribute to the destabil-
ization of synaptic contacts and therefore are likely to
have a significant impact on memory circuits (Cochran
et al., 2014). More importantly, these changes occur at
early stages of the disease, a period now considered to be
critical for successful therapeutic interventions (Korolev,
2014). Within this context, our key finding is that Ab
drives the weakening of postsynaptic M1 mAChR func-
tion by aberrantly activating mGluR5. Since mAChR
functions to affect a number of signal cascades, weaken-
ing of postsynaptic mAChR may have fundamental
pathophysiological consequences, likely impacting on syn-
aptic function and structure. For instance, weakening of
mAChR may lead to aberrant activation of NMDAR in
the perirhinal cortex (Jo et al., 2010). Therefore, Ab-
mediated weakening of mAChR could also link to the
regulation of a glycogen synthase kinase 3 signalling, one
of the major Alzheimer’s disease-related synapse-weaken-
ing molecules (Jo et al., 2011; Regan et al., 2015).
Within the limited therapeutic options available for
Alzheimer’s disease, memantine is a widely used
NMDAR blocker. We previously reported that meman-
tine restored object recognition memory by blocking false
memory in the TG CRND8 mouse model of Alzheimer’s
disease (Romberg et al., 2012). This showed that the ab-
errant activation of NMDARs causes pathophysiological
synaptic plasticity and may dysregulate cellular mecha-
nisms of object recognition memory in Alzheimer’s
disease. Interestingly, our current study showed that Ab-
mediated weakening of mAChR function was Ca2þ
mobilization and NMDAR dependent. This suggests the
notion that Ab inhibits mAChR function via either
mGluR5 or through synergistic regulation between the
mGluR5 and NMDARs. Since mGluR5 antagonism alone
rescues mAChR function and object recognition memory,
tight control of mGluR5 function will be an advanta-
geous for the maintenance of mAChR function and pre-
venting the progress of pathology and enhancing
cognitive performance, as we have shown in this study.
Though previous studies have demonstrated that a
broad conceptual role of mGluR5 antagonism is the res-
toration of memory function in TG mouse models of
Alzheimer’s disease (e.g. Hamilton et al., 2016), our
study provides a framework for these effects: the aberrant
activation of mGluR5 impairing postsynaptic mAChR
function, where through blocking mGluR5, postsynaptic
mAChR function and object recognition memory in
Alzheimer’s disease models can be restored. Thus, we
postulate that mGluR5-mediated dysfunction of postsy-
naptic mAChRs underlies a potential cellular mechanism
of object recognition memory deficit in Alzheimer’s dis-
ease. This positions mAChR as a further potential thera-
peutic target when considering how to prevent
acetylcholine-signalling decline in the developing path-
ology of Alzheimer’s disease.
Supplementary material
Supplementary material is available at Brain
Communications online.
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